Stada widens biotech drug offering with filgrastim license

FRANKFURT (Reuters) - Germany's Stada will sell a version of U.S. drugmaker Amgen's blockbuster cancer treatment filgrastim in Europe, keeping faith with the difficult market for copies of medicines developed using biotechnology. The German generic drugmaker said on Monday it agreed with Canada's Apotex Inc., which developed a filgrastim version based on Amgen's original, to market the drug in nearly all European Union countries. ...

via Health News Headlines - Yahoo! News http://news.yahoo.com/stada-widens-biotech-drug-offering-filgrastim-license-130254737--finance.html